1.
|
Phase: Phase IV Type: Treatment Status: Active Age: 1 to 18 Sponsor: Other Protocol IDs: UKALL2003, NCT00222612
|
|
2.
|
Phase: Phase IV Type: Treatment Status: Active Age: 1 to 14 Sponsor: Other Protocol IDs: 2005-000658-56, 20040177, 2004-41-4276, NCT00192673
|
|
3.
|
Phase: Phase IV Type: Treatment Status: Active Age: 15 and under Sponsor: Other Protocol IDs: LAL-BR/2001, NCT00526175
|
|
4.
|
Phase: Phase IV Type: Treatment Status: Active Age: 16 and under Sponsor: Other Protocol IDs: LAL-AR-N-2005, NCT00526409
|
|
5.
|
Phase: Phase IV Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: SCT 0208, NCT00679536
|
|
6.
|
Phase: Phase IV Type: Treatment Status: Active Age: 16 and under Sponsor: Other Protocol IDs: 2007016, NCT00846703
|
|
7.
|
Phase: Phase IV Type: Treatment Status: Approved-not yet active Age: 21 and under Sponsor: Other Protocol IDs: TASMC-11-MB-442-CTIL, NCT01339988
|
|
8.
|
Phase: Phase IV Type: Treatment Status: Active Age: 55 and under Sponsor: Other Protocol IDs: LAL Ph-2008, NCT01491763
|
|
9.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 35 and under Sponsor: Other Protocol IDs: 2000LS040, MT2000-12, 0005M52481, UMN-2000LS040, NCT00176839
|
|
10.
|
Phase: Phase III, Phase II Type: Supportive care, Treatment Status: Active Age: 0 to 18 Sponsor: Other Protocol IDs: CHU-0060, NCT01007617
|
|
11.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 1 to 50 Sponsor: Other Protocol IDs: HORCSCT-0902, NCT01015742
|
|
12.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 1 to 17 Sponsor: Other Protocol IDs: CDR0000686545, GPOH-COALL-08-09, EUDRACT-2009-012758-18, EU-21076, NCT01228331
|
|
13.
|
Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 to 55 Sponsor: Pharmaceutical / Industry Protocol IDs: GRASPALL2009-06, NCT01518517
|
|
14.
|
Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and under Sponsor: NCI Protocol IDs: COG-ANHL1131, ANHL1131, NCT01595048
|
|
15.
|
Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 3 to 20 Sponsor: NCI Protocol IDs: SCUSF-0402, HLMCC-0402, NCT00369564, ACCL 0731
|
|
16.
|
Phase: Phase III Type: Treatment Status: Active Age: 1 to under 30 Sponsor: NCI Protocol IDs: COG-AALL0433, AALL0433, NCT00381680
|
|
17.
|
Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 1 to under 22 at first relapse Sponsor: NCI Protocol IDs: COG-ASCT0431, ASCT0431, COG-PBMTC-ONCO51, NCT00382109
|
|
18.
|
Phase: Phase III Type: Treatment Status: Active Age: 1 to 18 Sponsor: Other Protocol IDs: CDR0000528029, ALL-BFM-2000, EU-20682, NCT00430118
|
|
19.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 and under at diagnosis Sponsor: NCI Protocol IDs: COG-AALL0631, AALL0631, NCT00557193
|
|
20.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and under Sponsor: NCI, Other Protocol IDs: TOTXVI, 5R01CA140729, 5F32CA141762, NCT00549848
|
|
21.
|
Phase: Phase III Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: SCT 0307, NCT00619879
|
|
22.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and under Sponsor: Other Protocol IDs: CDR0000613220, MOTOL-ALL-IC-BFM-2002, EU-20871, ALL-IC-BFM-2002, NCT00764907
|
|
23.
|
Phase: Phase III Type: Treatment Status: Active Age: 1 to 17 Sponsor: Other Protocol IDs: NOPHO ALL2008 consolidation, NCT00816049
|
|
24.
|
Phase: Phase III Type: Treatment Status: Active Age: 1 to 17 Sponsor: Other Protocol IDs: NOPHO ALL2008 PEG Asparaginase, NCT00819351
|
|
25.
|
Phase: Phase III Type: Treatment Status: Active Age: 1 to 18 Sponsor: Other Protocol IDs: CCLG-ALLR3, CCLG-ALLR3, ISCRTN-45724312, EUDRACT-2004-000052-16, EU-20938, NCT00967057
|